Publication: Recommendations by the Asian Pacific society of nephrology (APSN) on the appropriate use of HIF-PH inhibitors
Issued Date
2021-02-01
Resource Type
ISSN
14401797
13205358
13205358
Other identifier(s)
2-s2.0-85097306486
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
Nephrology. Vol.26, No.2 (2021), 105-118
Suggested Citation
Desmond Y.H. Yap, Lawrence P. McMahon, Chuan Ming Hao, Nan Hu, Hirokazu Okada, Yusuke Suzuki, Sung Gyun Kim, Soo Kun Lim, Kriengsak Vareesangthip, Chi Chih Hung, Masaomi Nangaku Recommendations by the Asian Pacific society of nephrology (APSN) on the appropriate use of HIF-PH inhibitors. Nephrology. Vol.26, No.2 (2021), 105-118. doi:10.1111/nep.13835 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/78495
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Recommendations by the Asian Pacific society of nephrology (APSN) on the appropriate use of HIF-PH inhibitors
Other Contributor(s)
Graduate School of Medicine
Peking University First Hospital
Kaohsiung Medical University Chung-Ho Memorial Hospital
Saitama Medical University
Hallym University
University of Malaya Medical Centre
Faculty of Medicine, Nursing and Health Sciences
Faculty of Medicine Siriraj Hospital, Mahidol University
Fudan University
Juntendo University School of Medicine
The University of Hong Kong
Peking University First Hospital
Kaohsiung Medical University Chung-Ho Memorial Hospital
Saitama Medical University
Hallym University
University of Malaya Medical Centre
Faculty of Medicine, Nursing and Health Sciences
Faculty of Medicine Siriraj Hospital, Mahidol University
Fudan University
Juntendo University School of Medicine
The University of Hong Kong
Abstract
Renal anaemia is a common and important complication in patients with chronic kidney disease (CKD). The current standard-of-care treatment for renal anaemia in CKD patients involves ensuring adequate iron stores and administration of erythropoietin stimulating agents (ESA). Hypoxia inducible factor (HIF) is a key transcription factor primarily involved in the cellular regulation and efficiency of oxygen delivery. Manipulation of the HIF pathway by the use of HIF-prolyl hydroxylase inhibitors (HIF-PHI) has emerged as a novel approach for renal anaemia management. Despite it being approved for clinical use in various Asia-Pacific countries, its novelty mandates the need for nephrologists and clinicians generally in the region to well understand potential benefits and harms when prescribing this class of drug. The Asian Pacific society of nephrology HIF-PHI Recommendation Committee, formed by a panel of 11 nephrologists from the Asia-Pacific region who have clinical experience or have been investigators in HIF-PHI studies, reviewed and deliberated on the clinical and preclinical data concerning HIF-PHI. This recommendation summarizes the consensus views of the committee regarding the use of HIF-PHI, taking into account both available data and expert opinion in areas where evidence remains scarce.